Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients

Pediatric Transplantation

Volumn 6, Issue 2, 2002, Pages 124-126

  Reding, Raymond ^a   Sokal, Etienne ^a   Paul, Killick ^a   Janssen, Magda ^a   Evrard, Veerle ^a   Wilmotte, Léon ^a   Chardot, Christophe ^b   Otte, Jean Bernard ^a   Wallemacq, Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Children; Liver; Tacrolimus; Transplantation

Indexed keywords

STEROID; TACROLIMUS;

ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; GRAFT REJECTION; HUMAN; LIVER TRANSPLANTATION; SURVIVAL RATE;

ADMINISTRATION, ORAL; CAPSULES; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; PEDIATRICS; SUSPENSIONS; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 0036256907     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2002.01052.x     Document Type: Article

References (10)

1. FK 506 for liver, kidney, and pancreas transplantation
2. FK 506 (tacrolimus), a novel immunosuppressant in organ transplantation: Clinical, biomedical and analytical aspects
3. Conversion from cyclosporine A to FK 506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity and dose regimen in 23 children
4. Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients
5. Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients
6. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients
7. Stability of tacrolimus in an extemporaneously compounded oral liquid
8. IMx tacrolimus II vs IMx tacrolimus microparticle enzyme immunoassay evaluated in renal and hepatic transplant patients
9. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression
10. A comparative study of FK506 granules and capsules in renal transplant recipients